ArticleAmerican journal of translational research2023
Efficacy and safety of Agatroban in improving the prognosis of ischemic stroke patients.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- The Crosstalk Between Ferritinophagy and Ferroptosis in Ischemic Stroke: Regulatory Mechanisms and Therapeutic Implications.Cellular and molecular neurobiology · 2025Review
- A New Perspective in the Treatment of Ischemic Stroke: Ferroptosis.Neurochemical research · 2024Review
- Ferroptosis inhibitors: past, present and future.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore and analyze the efficacy and safety of combined treatment of Agatroban and Aspirin in improving short-term and long-term prognosis of ischemic stroke patients.
methodsIn this retrospective study, the clinical data of patients with ischemic stroke admitted to the Department of Neurology, Songjiang Sijing Hospital from June 2021 to April 2023 were analyzed. A total of 108 patients were selected according to the inclusion and exclusion criteria, including 54 patients treated with Aspirin only, named the control group, and 54 patients treated with Agatroban plus Aspirin, named the study group.
resultsCompared with the control group, the study group had a higher effective rate (P=0.047). There was no significant difference in MIESSS and daily living ability scores between the two groups before treatment (P>0.05). After treatment, compared with the control group, the study group had a lower MIESSS score and a higher daily living ability score (P=0.035; P=0.044). There was no significant difference in coagulation indicators between the two groups before treatment (P>0.05). After treatment, compared with the control group, the study group had lower platelet count, fibrinogen, and D-dimer levels (P=0.031; P=0.042; P=0.047). There was no significant difference in inflammatory cytokines between the two groups before treatment (P>0.05). After treatment, compared with the control group, the study group showed significantly decreased tumor necrosis factor (TNF)-α, interleukin-6 (IL-6) and interleukin-8 (IL-8) (P=0.041; P=0.038; P=0.046). Compared with the control group, the incidence of adverse reactions in the study group was lower (P=0.033), while the prognosis was better (P=0.029; P=0.033; P=0.048).
conclusionCompared with Aspirin alone, Argatroban plus Aspirin can optimize coagulation parameters to a greater extent and reduce the level of cellular inflammatory factors, further improve the body's neurological functions, remarkably reduce the occurrence of adverse prognosis, and enhance the patient's ability of daily living, with remarkable therapeutic effect.
Indexed as
Identifiers
37854211PMC10579034W4387764876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.